You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS).
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.